Page 3 - ஜான் ட்‌ஸை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜான் ட்‌ஸை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜான் ட்‌ஸை Today - Breaking & Trending Today

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

NOVARTIS AG CHF0.50(REGD)
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase
1
In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept ....

United States , United Kingdom , Isabella Zinck , Rachel Fink , Lookeren Campagne , Thomas Hungerbuehler , Amy Wolf , Samir Shah , Julie Masow , Beovu Basel , Sloan Simpson , John Tsai , Novartis Division Communications , World Health Organization , Global Head Of Drug Development , Novartis External Communications , Health Qual Life Outcomes , Exchange Commission , Canadian Drug Expert Committee Recommendation , National Eye Institute , National Health Insurance Pricing , European Society Of Retina Specialists , Canadian Agency For Drugs , Technologies In Health , Lancet Glob Health , Global Head ,

Novartis Pharma AG: Novartis reports one year results of Phase III MERLIN study evaluating Beovu every four week dosing and provides update on Beovu clinical program

Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept ....

United States , United Kingdom , Isabella Zinck , Rachel Fink , Lookeren Campagne , Thomas Hungerbuehler , Amy Wolf , Samir Shah , Julie Masow , Beovu Basel , Sloan Simpson , John Tsai , Novartis Division Communications , World Health Organization , Global Head Of Drug Development , Novartis External Communications , Health Qual Life Outcomes , Exchange Commission , Canadian Drug Expert Committee Recommendation , National Eye Institute , National Health Insurance Pricing , European Society Of Retina Specialists , Canadian Agency For Drugs , Technologies In Health , Lancet Glob Health , Global Head ,

Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

/PRNewswire/ Today, Novartis reported the first interpretable year one results of the Phase III MERLIN study, a two-year study initiated in H2 2018,. ....

United States , United Kingdom , Lookeren Campagne , Beovu Basel , John Tsai , Health Qual Life Outcomes , National Eye Institute , National Health Insurance Pricing , Technologies In Health , World Health Organization , Global Head Of Drug Development , Canadian Drug Expert Committee Recommendation , Exchange Commission , Nj Novartis Pharmaceuticals Corporation , Novartis Pharmaceuticals Corporation , Canadian Agency For Drugs , European Society Of Retina Specialists , Lancet Glob Health , Global Head , Drug Development , Chief Medical Officer , North America , Age Related Macular Degeneration , Retinal Vascular , East Hanover , Pharmaceuticals Corporation ,

Novartis' canakinumab failed to improve survival in COVID-19 study

Novartis’ canakinumab failed to improve survival in COVID-19 study
Swiss pharma company had been studying drug in hospitalised COVID-19 patients
Novartis’ arthritis drug canakinumab failed to hit its primary endpoint of improving survival for COVID-19 patients without the need for invasive mechanical ventilation, the Swiss pharma company announced today.
Novartis had been studying the drug in hospitalised patients with COVID-19 pneumonia and cytokine release syndrome (CRS).
The trial failed to show that treatment with canakinumab plus standard of care demonstrated a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with standard of care at day 29. ....

Roche Actemra , Regeneron Kevzara , John Tsai , Molecular Partners , ஜான் ட்‌ஸை , மூலக்கூறு கூட்டாளர்கள் ,

Novartis (NVS) Q1 2021 Earnings Call Transcript

Novartis (NVS) Q1 2021 Earnings Call Transcript
Motley Fool Transcribing
© The Motley Fool
Logo of jester cap with thought bubble.
Novartis (NYSE: NVS)
Good morning and good afternoon, and welcome to the Novartis Q1 2021 results release conference call and live audio webcast. Please note that during the presentation, all participants will be on a listen-only mode and the conference is being recorded. [Operator instructions] A recording of the conference call including the Q&A session will be available on our website shortly after the call ends. [Operator instructions] With that, I would like to hand it over to Mr.
Samir Shah, global head of investor relations. Please go ahead, sir. ....

United States , Czech Republic , Graham Parry , Matthew Weston , Andrew Baum , Susanne Schaffert , Laura Sutcliffe , Harry Kirsch , Samir Shah , Andrew Baum Citi , Simon Baker Redburn , Keyur Parekh , Mike Nedelcovych , Tom Kendris , John Tsai , Richard Parkes , Tim Anderson , Florent Cespedes , Richard Wagner , Societe Generale , Richard Parkes Exane , Florent Cespedes Societe Generale , Mark Purcell , Simon Baker , Exjade Jadenu , Emmanuel Papadakis ,